airsonea era & mhealth global ldrshp in asthma

Annual Report is very worthwhile reading, especially chairman's letter, and Review of Operations (ROO)by Mike Thomas. Similarly have a look at company presentation on day of Aussie launch on Isonea website.

Note in the final few paras of Chairman's letter "the creation of additional innovations" and "we view the year ahead as the INITIATION of The Airsonea Era".

In the ROO, Mike concludes with "the RAMP to mhealth global leadership in asthma starts here". What definition of RAMP did he have in mind when writing this ? I hope both definitions.

Both make comment of Juniper Research "mushroom effect" when healthcare providers start realising the cost savings of smartphone connected remote self monitoring devices.
Imagine the scenario of ONE major health provider that has 50,000 asthmatic customers and decides to provide each of them with an Airsonea wheeze monitoring device.

At $130 that would equate to initial sales turnover of $6.5 million and ongoing subscription annual fees in excess of $1 million. In the U.S. an average two day stay in hospital can cost in excess of $20,000. Keeping 325 asthmatics out of hospital in the first year would cover their investment. This represents LESS than ONE percent of their asthmatic customers. This is a non brainer (even for health providers)!!

I don't think most people realize that upon FDA approval we are looking at exponential growth.

BLOKES: You are being very conservative in predicting +30 cents upon FDA approval. i.e. share price between $1.00 - $ 1.10.

Upon FDA approval stock will be well north of $1.50.
Within 12 months of U.S. launch Isonea should have met the current sales figure of $110 mill of Dexcom. Where will the share price be Dec 2014 if the market gives us a similar market capp of Dexcom. I'll let you do the numbers.

CLUE: North of $7.00